Long-Term Survival Results of Surgery Alone Versus Surgery plus UFT (Uracil and Tegafur)-Based Adjuvant Therapy in Patients with Stage II Colon Cancer

Been Ren Lin, Hong Shiee Lai, Tung Cheng Chang, Po Huang Lee, King Jen Chang, Jin Tung Liang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: It is well established that adjuvant chemotherapy with 5-fluouracil and leucovorin (5-FU/LV) improves survival for patients with resected colon cancer; however, the benefits of oral uracil and tegafur (UFT) chemotherapy in these patients are still uncertain. Methods: All patients enrolled in this retrospective study with stage II disease who were treated with surgery or surgery plus UFT were examined to determine the overall survival and disease-free interval. Time-to-event by treatment group was examined using Kaplan-Meier estimates and multivariable Cox regression analysis. Results: There were 456 eligible patients-217 (47. 5%) patients had surgery and 239 (52. 5%) patients had surgery plus UFT. In patients aged ≥65 years, deeper tumor depth and fewer nodes observed were associated with lower survival. The 5-year survival rate was 84. 2% in the surgery group and 89. 1% in the surgery plus UFT group (P = 0. 006). Treatment with UFT after surgery was associated with improved outcome compared with surgery alone: overall survival (HR = 0. 611, P = 0. 018) and disease-free survival (HR = 0. 590, P = 0. 032). Conclusions: Oral fluoropyrimidines improve the disease-free rate and the overall survival of patients after resection of stage II colon cancer. These observations support the use of these agents following surgery as it provides a benefit over surgery alone.

Original languageEnglish
Pages (from-to)2239-2245
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Tegafur
Uracil
Colonic Neoplasms
Survival
Therapeutics
Disease-Free Survival
Survival Rate
Leucovorin
Kaplan-Meier Estimate
Adjuvant Chemotherapy
Retrospective Studies
Regression Analysis

Keywords

  • Adjuvant chemotherapy
  • Colon cancer
  • UFT

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Long-Term Survival Results of Surgery Alone Versus Surgery plus UFT (Uracil and Tegafur)-Based Adjuvant Therapy in Patients with Stage II Colon Cancer. / Lin, Been Ren; Lai, Hong Shiee; Chang, Tung Cheng; Lee, Po Huang; Chang, King Jen; Liang, Jin Tung.

In: Journal of Gastrointestinal Surgery, Vol. 15, No. 12, 12.2011, p. 2239-2245.

Research output: Contribution to journalArticle

@article{d6b4e2a279bd49d9acbf967c23cf2925,
title = "Long-Term Survival Results of Surgery Alone Versus Surgery plus UFT (Uracil and Tegafur)-Based Adjuvant Therapy in Patients with Stage II Colon Cancer",
abstract = "Background: It is well established that adjuvant chemotherapy with 5-fluouracil and leucovorin (5-FU/LV) improves survival for patients with resected colon cancer; however, the benefits of oral uracil and tegafur (UFT) chemotherapy in these patients are still uncertain. Methods: All patients enrolled in this retrospective study with stage II disease who were treated with surgery or surgery plus UFT were examined to determine the overall survival and disease-free interval. Time-to-event by treatment group was examined using Kaplan-Meier estimates and multivariable Cox regression analysis. Results: There were 456 eligible patients-217 (47. 5{\%}) patients had surgery and 239 (52. 5{\%}) patients had surgery plus UFT. In patients aged ≥65 years, deeper tumor depth and fewer nodes observed were associated with lower survival. The 5-year survival rate was 84. 2{\%} in the surgery group and 89. 1{\%} in the surgery plus UFT group (P = 0. 006). Treatment with UFT after surgery was associated with improved outcome compared with surgery alone: overall survival (HR = 0. 611, P = 0. 018) and disease-free survival (HR = 0. 590, P = 0. 032). Conclusions: Oral fluoropyrimidines improve the disease-free rate and the overall survival of patients after resection of stage II colon cancer. These observations support the use of these agents following surgery as it provides a benefit over surgery alone.",
keywords = "Adjuvant chemotherapy, Colon cancer, UFT",
author = "Lin, {Been Ren} and Lai, {Hong Shiee} and Chang, {Tung Cheng} and Lee, {Po Huang} and Chang, {King Jen} and Liang, {Jin Tung}",
year = "2011",
month = "12",
doi = "10.1007/s11605-011-1722-4",
language = "English",
volume = "15",
pages = "2239--2245",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Long-Term Survival Results of Surgery Alone Versus Surgery plus UFT (Uracil and Tegafur)-Based Adjuvant Therapy in Patients with Stage II Colon Cancer

AU - Lin, Been Ren

AU - Lai, Hong Shiee

AU - Chang, Tung Cheng

AU - Lee, Po Huang

AU - Chang, King Jen

AU - Liang, Jin Tung

PY - 2011/12

Y1 - 2011/12

N2 - Background: It is well established that adjuvant chemotherapy with 5-fluouracil and leucovorin (5-FU/LV) improves survival for patients with resected colon cancer; however, the benefits of oral uracil and tegafur (UFT) chemotherapy in these patients are still uncertain. Methods: All patients enrolled in this retrospective study with stage II disease who were treated with surgery or surgery plus UFT were examined to determine the overall survival and disease-free interval. Time-to-event by treatment group was examined using Kaplan-Meier estimates and multivariable Cox regression analysis. Results: There were 456 eligible patients-217 (47. 5%) patients had surgery and 239 (52. 5%) patients had surgery plus UFT. In patients aged ≥65 years, deeper tumor depth and fewer nodes observed were associated with lower survival. The 5-year survival rate was 84. 2% in the surgery group and 89. 1% in the surgery plus UFT group (P = 0. 006). Treatment with UFT after surgery was associated with improved outcome compared with surgery alone: overall survival (HR = 0. 611, P = 0. 018) and disease-free survival (HR = 0. 590, P = 0. 032). Conclusions: Oral fluoropyrimidines improve the disease-free rate and the overall survival of patients after resection of stage II colon cancer. These observations support the use of these agents following surgery as it provides a benefit over surgery alone.

AB - Background: It is well established that adjuvant chemotherapy with 5-fluouracil and leucovorin (5-FU/LV) improves survival for patients with resected colon cancer; however, the benefits of oral uracil and tegafur (UFT) chemotherapy in these patients are still uncertain. Methods: All patients enrolled in this retrospective study with stage II disease who were treated with surgery or surgery plus UFT were examined to determine the overall survival and disease-free interval. Time-to-event by treatment group was examined using Kaplan-Meier estimates and multivariable Cox regression analysis. Results: There were 456 eligible patients-217 (47. 5%) patients had surgery and 239 (52. 5%) patients had surgery plus UFT. In patients aged ≥65 years, deeper tumor depth and fewer nodes observed were associated with lower survival. The 5-year survival rate was 84. 2% in the surgery group and 89. 1% in the surgery plus UFT group (P = 0. 006). Treatment with UFT after surgery was associated with improved outcome compared with surgery alone: overall survival (HR = 0. 611, P = 0. 018) and disease-free survival (HR = 0. 590, P = 0. 032). Conclusions: Oral fluoropyrimidines improve the disease-free rate and the overall survival of patients after resection of stage II colon cancer. These observations support the use of these agents following surgery as it provides a benefit over surgery alone.

KW - Adjuvant chemotherapy

KW - Colon cancer

KW - UFT

UR - http://www.scopus.com/inward/record.url?scp=81355146524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81355146524&partnerID=8YFLogxK

U2 - 10.1007/s11605-011-1722-4

DO - 10.1007/s11605-011-1722-4

M3 - Article

C2 - 21993974

AN - SCOPUS:81355146524

VL - 15

SP - 2239

EP - 2245

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 12

ER -